NCT07017231Active, not recruiting
Role of Interleukin-13 Pathways on Pain and Itch Sensitivity ( IL-13 )
The Role of the Interleukin-13 Pathways on Pain and Itch Sensitivity in Patients With Atopic Dermatitis and Healthy Volunteers
Source: ClinicalTrials.gov · Last updated 12 Jun 2025
Brief summary (registry, in English)
Atopic dermatitis (AD) is as chronic, inflammatory skin disorder affecting 20% of the world's population. Intense itch and skin pain are the main symptoms. Research has shown that the proteins interleukins are involved in inflammation and itch in atopic dermatitis. The medicinal product called Lebrikizumab, used for treatment of AD, has shown to block the interleukin called IL-13. The purpose of this experiment is to evaluate the role of IL-13 in itch in people with atopic dermatitis.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- First submitted
- 30 May 2025
- Start date
- 15 May 2025
- Primary completion date
- 31 Dec 2025
- Lead sponsor
- Aalborg University
- Diseases
- Atopic dermatitis (eczema)
- NCT number
- NCT07017231
What you commit to
- Study type: Interventional
- Planned participants: 26
- From 15 May 2025 to the primary completion date, 31 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnancy or lactation
- Drug addiction defined as any use of cannabis, opioids, or other drugs Moles, wounds, scars, or tattoos in the area to be treated or tested
- Treatment within two weeks before start of the experiment with topical corticosteroids or calcineurin inhibitors.
- Treatment within two weeks before start of the experiment with topical treatments (excluding emollients) on the skin areas selected for testing (eight weeks if treated with systemic treatments for AD such as methotrexate or azathioprine)
- Treatment with antihistamines 72 hours before start of the experiment
- Previous or current history of neurological, musculoskeletal, cardiac disorder, or psychiatric diagnoses that may affect the results (e.g., neuropathy, muscular pain in the upper extremities, anxiety, depression, schizophrenia, etc.)
- Current use of medications that may affect the trial such as antihistamines and painkillers (use of antihistamines must be discontinued 72 hours before the experiment and all topical agents and emollients must be discontinued 24 hours before the experiment).
- Use of systemic corticosteroids
- Consumption of alcohol or painkillers 24 hours before the study days and between these
- Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)
- Lack of ability to cooperate
Who the study is looking for
- 18-60 years • The patients should have an AD according to diagnosis by a board-certified dermatologist, with an Eczema Area and Severity Index (EASI), a validated scoring tool that grades the physical signs of AD of at least 7. The project team will be specifically trained and evaluated in the EASI assessment to ensure interindividual consistency.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Neuroplasticity and Pain Faculty of Medicine, Aalborg University Selma Lagerløfs Vej 249 9260 Gistrup, Denmark Coordinator of this site? Confirm its status | Gistrup | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.